

# **Medical Al Ensemble Clinical Decision Report**

Generated: 2025-08-12 Case ID: Case\_13 Title: Case\_13 - Medical Analysis

06:43

# **Primary Diagnostic Consensus**

Diagnosis	ICD-10	Agreement	Confidence	Status
Iga Nephropathy Evidence: Fever, Pain, Hypertension	M32.14	63.6%	High	PRIMARY

## **Alternative & Minority Diagnoses**

Diagnosis	ICD-10	Support	Туре
Lupus Nephritis	Unknown	45.5%	Strong Alt (≥30%)
Post-infectious Glomerulonephritis	Unknown	36.4%	Strong Alt (≥30%)
Systemic Lupus Erythematosus  Evidence: Joint pain, Fatigue, Skin rash	M32.9	31.8%	Strong Alt (≥30%)
Interstitial Nephritis	Unknown	22.7%	Alternative (20-29%)
Glomerulonephritis	Unknown	18.2%	Alternative (20-29%)
Membranoproliferative Glomerulonephritis	Unknown	18.2%	Alternative (20-29%)
Renal Cell Carcinoma	Unknown	13.6%	Alternative (20-29%)
Anca-associated Vasculitis	Unknown	13.6%	Alternative (20-29%)
Interstitial Cystitis	Unknown	9.1%	Minority (<20%)
Chronic Kidney Disease	Unknown	9.1%	Minority (<20%)
Membranous Nephropathy	Unknown	9.1%	Minority (<20%)
Chronic Pyelonephritis	Unknown	9.1%	Minority (<20%)
Rapidly Progressive Glomerulonephritis	Unknown	9.1%	Minority (<20%)

Analysis Overview
Models Queried: 22
Successful Responses: 22
Consensus Level: Moderate
Total Estimated Cost: \$0.385

# **Critical Decision Points & Evidence Synthesis**

### **Critical Decision Points**

Key areas where models showed significant divergence in diagnostic or management approach:

## **Evidence Synthesis & Clinical Correlation**

# **Symptom-Diagnosis Correlation Matrix**

Symptom/Finding	lga Nephropa	Lupus Nephri	Post-infecti	Systemic Lup
Hypertension	+++	+	+	+
Primary Clinica	+++	+++	+++	+++
Fever	+++	-	-	-
Pain	+++	++	++	++

Legend: +++ Strong association, ++ Moderate, + Weak, - Not typical

## **Diagnostic Decision Tree**

Step	Action	If Positive	If Negative
1	Initial Laboratory Tests	→ Confirm suspicion	$\rightarrow$ Broaden differential
2	Imaging Studies	ightarrow Identify pathology	→ Consider specialized tests
3	Specialized Testing	→ Definitive diagnosis	→ Empiric treatment
4	Treatment Trial	→ Continue if effective	→ Reconsider diagnosis

# **Executive Summary**

### **Case Description**

Complex Urology Case Presentation

Patient Demographics

Age: 24 years old

Sex: Male

Ethnicity: Middle Eastern (Iranian heritage) Occupation: Graduate student in chemistry

**Chief Complaint** 

"Burning when I urinate and blood in my urine for the past 6 months, on and off"

History of Present Illness

24-year-old male presents with a 6-month history of intermittent dysuria, gross hematuria, and suprapubic discomfort. Episodes occur every 2-3 weeks, last 3-5 days, then resolve completely. Patient reports no fever during episodes. Pain is described as "deep burning" both during and after urination. Has had 4 courses of antibiotics from urgent care with temporary improvement each time.

Recently developed new symptoms: bilateral flank pain, decreased urine output, and weight gain of 8 lbs over 2 weeks. Denies recent travel, new sexual partners, or illicit drug use. Reports family history of "kidney problems" in paternal uncle.

Past Medical History

- Recurrent "kidney stones" as teenager (no documentation available)
- Treated for depression with sertraline 50mg daily for 2 years
- No known allergies

Social History

- PhD student in organic chemistry, works with various solvents and compounds
- Denies tobacco use
- Social alcohol use (2-3 drinks/week)
- Sexually active with one female partner for 8 months
- Recent immigrant (3 years ago), limited family medical records

Physical Examination

- Vital Signs: BP 145/92, HR 88, Temp 37.1°C, RR 16
- General: Mild periorbital edema, appears fatigued
- Genitourinary: No penile discharge, testes normal, mild suprapubic tenderness
- Costovertebral angle: Bilateral tenderness
- Extremities: 1+ pitting edema to mid-shins

Laboratory Results

Urinalysis (during symptomatic episode)

- Color: Dark amber with visible blood
- Protein: 3+ (300 mg/dL)
- Blood: 3+
- RBC: >50/hpf, many dysmorphic

- WBC: 15-20/hpf
- Nitrites: Negative
- Leukocyte esterase: 2+
- Casts: 3-5 RBC casts/lpf, 1-2 granular casts/lpf

#### **Urine Culture**

- Day 1: Mixed flora <10,000 CFU/mL
- Day 3: No growth

#### Serum Chemistry

- Creatinine: 2.1 mg/dL (baseline unknown)
- BUN: 45 mg/dL
- eGFR: 42 mL/min/1.73m<sup>2</sup>
- Sodium: 138 mEq/L
- Potassium: 4.8 mEq/L
- Chloride: 104 mEq/L

#### Additional Labs

- CBC: WBC 8,200, Hgb 11.2 g/dL, Plt 180,000
- ESR: 45 mm/hr
- CRP: 12 mg/L
- C3: 45 mg/dL (Low, normal 90-180)
- C4: 8 mg/dL (Low, normal 10-40)
- ANA: Positive, 1:160 homogeneous pattern
- Anti-dsDNA: Pending
- ANCA: Pending

#### **Imaging**

- Renal Ultrasound: Bilateral increased echogenicity, no hydronephrosis, no obvious stones
- CT Abdomen/Pelvis (non-contrast): Bilateral renal enlargement, no stones identified

# **Key Clinical Findings**

- Elevated inflammatory markers (CRP, ESR)
- · Positive family history of similar episodes

# **Primary Recommendations**

- Moderate consensus (63.6%) suggests Iga Nephropathy
- Initiate treatment for Iga Nephropathy
- Symptomatic management

# **Primary Diagnosis Clinical Summaries**

Orchestrated analysis not available for this case.

# **Diagnostic Landscape Analysis**

### **Detailed Diagnostic Analysis**

The ensemble analysis identified **Iga Nephropathy** as the primary diagnosis with 63.6% consensus among 14 models.

## **Detailed Alternative Analysis**

Diagnosis	Support	Key Evidence	Clinical Significance
Lupus Nephritis	45.5%	10 models	Worth investigating
Post-infectious Glomerulonephritis	36.4%	8 models	Worth investigating
Systemic Lupus Erythematosus Evidence: Joint pain, Fatigue, Skin rash	31.8%	7 models	Worth investigating
Interstitial Nephritis	22.7%	5 models	Less likely
Glomerulonephritis	18.2%	4 models	Less likely
Membranoproliferative Glomerulonephritis	18.2%	4 models	Less likely
Renal Cell Carcinoma	13.6%	3 models	Less likely
Anca-associated Vasculitis	13.6%	3 models	Less likely

# **Minority Opinions**

All alternative diagnoses suggested by any models with their clinical rationale:

• Interstitial Cystitis (ICD-10: Unknown) - 9.1% agreement (2 models)

Supporting Models: mistral-7b-instruct, grok-4

• Chronic Kidney Disease (ICD-10: Unknown) - 9.1% agreement (2 models)

Supporting Models: mistral-7b-instruct, grok-4

• Membranous Nephropathy (ICD-10: Unknown) - 9.1% agreement (2 models)

Supporting Models: mistral-7b-instruct, grok-4

• Chronic Pyelonephritis (ICD-10: Unknown) - 9.1% agreement (2 models)

Supporting Models: mistral-7b-instruct, grok-4

• Rapidly Progressive Glomerulonephritis (ICD-10: Unknown) - 9.1% agreement (2 models)

Supporting Models: mistral-7b-instruct, grok-4

# **Management Strategies & Clinical Pathways**

# **Immediate Actions Required**

Priority	Action	Rationale	Consensus
1	Initiate treatment for Iga Nephropathy	Evidence-based management of primary condition	High
2	Symptomatic management	Patient comfort and stabilization	High

# **Recommended Diagnostic Tests**

Test	Purpose	Priority	Timing
Comprehensive diagnostic workup	Confirm Iga Nephropathy diagnosis	High	As indicated
Laboratory studies	Assess disease activity and complications	Routine	As indicated

### **Treatment Recommendations**

Treatment recommendations pending diagnostic confirmation.

# **Model Diversity & Bias Analysis**

# **Model Response Overview & Cost Analysis**

Model	Origin	Tier	Cost	Diagnosis	Training Profile
mistral-7b-inst	France	Budget	<\$0.01	Renal Infection (Pyelonephritis)	General
grok-4	USA	Premium	\$0.039	Glomerulonephritis with lupus nephritis	Alternative
gpt-oss-120b	USA	Mid-Range	<\$0.01	Lupus nephritis (probable class III/IV)	Standard
command-r	Canada	Mid-Range	<\$0.01	Acute Pyelonephritis	Standard
deepseek-chat	China	Budget	<\$0.01	Lupus Nephritis	Regional
gemini-2.5-pro	USA	Premium	\$0.036	Not specified	General
deepseek-r1	China	Budget	<\$0.01	Not specified	Regional
sonar-deep-rese	USA	Premium	\$0.017	Lupus Nephritis	Standard
jamba-large-1.7	Israel	Premium	\$0.017	Lupus Nephritis	Standard
gemini-2.5-flas	USA	Budget	<\$0.01	Lupus Nephritis	General
mistral-large-2	France	Premium	\$0.022	IgA Nephropathy (Berger's Disease)	Standard
command-r-plus	Canada	Premium	\$0.028	Glomerulonephritis	Standard
wizardlm-2-8x22	USA	Mid-Range	<\$0.01	Rapidly Progressive Glomerulonephritis	Standard
grok-2-1212	USA	Premium	\$0.018	Lupus Nephritis	Standard
gemma-2-9b-it	USA	Budget	<\$0.01	Systemic Lupus Nephritis	Standard
gpt-4o	USA	Premium	\$0.028	IgA Nephropathy	Comprehensive
gemini-2.5-flas	USA	Budget	<\$0.01	Glomerulonephritis, likely related to autoimmune disease (e.g., Lupus Nephritis)	General
llama-3.2-3b-in	USA	Budget	<\$0.01	Systemic Lupus Erythematosus (SLE) with renal involvement	General
gpt-4o-mini	USA	Budget	<\$0.01	Glomerulonephritis	General
qwen-2.5-coder-	China	Mid-Range	<\$0.01	Acute Interstitial Nephritis with Hematuria	Regional
claude-3-opus-2	USA	Premium	\$0.158	Lupus nephritis	Comprehensive
lfm-40b	USA	Mid-Range	<\$0.01	Interstitial cystitis	Standard

<sup>\*\*</sup>Total Estimated Cost: \$0.385\*\*

# **Understanding Training Profiles**

Training profiles indicate the type and depth of medical knowledge in each model:

Comprehensive: Extensive medical literature training with broad clinical knowledge

Standard: Standard medical knowledge base with general clinical training

Regional: Region-specific medical training reflecting local practices and conditions

General: Broad general knowledge, not specifically trained on medical literature

Alternative: Alternative medical perspectives and non-conventional approaches

### **Al Model Bias Analysis**

Al model bias analysis is generated during orchestration (Step 2). This comprehensive analysis examines cultural, geographic, and training data biases across the Al models used.

#### Primary Diagnosis Bias Factors:

- Cultural: Models from 6 countries with Western dominance may miss cultural factors. Chinese models (18.2%) provide alternative perspective.
- Geographic: Western model dominance (109.1%) creates strong bias toward Western medical paradigms. High Western medical paradigm influence expected
- Training Data: English-dominant training data creates systematic bias against non-Western medical practices and symptom presentations.

#### Alternative Diagnoses Bias:

- Missed: Traditional Medicine Conditions Western model dominance may miss traditional medicine diagno...
- Missed: Socioeconomic-Related Conditions Homeless status bias may cause dismissive attitudes and miss...

#### Bias Mitigation Recommendations:

- Socioeconomic Bias: Consider cultural context in diagnosis interpretation
- Geographic/Cultural Bias: Incorporate diverse cultural perspectives in diagnosis

# **Detailed Model Responses**

Complete diagnostic assessments from each model:

### 1. mistral-7b-inst (France, Released: 2023-09-27)

**Primary Diagnosis:** Renal Infection (Pyelonephritis) (ICD-10: N10.90) - Confidence: 0.8 **Differential Diagnoses:** 

- Renal Cell Carcinoma (ICD: C64.9) 0.2
- Urolithiasis (Kidney Stones) (ICD: N13.9) 0.15
- Glomerulonephritis (ICD: B80.9) 0.1

#### **Key Clinical Findings:**

- Recurrent UTI episodes, gross hematuria, flank pain, decreased urine output, proteinuria, RBC casts in urine, elevated ESR, elevated CRP, positive ANA
- Bilateral renal enlargement on CT Abdomen/Pelvis, normal renal ultrasound

### 2. grok-4 (USA, Released: 2024-12-26)

### 3. gpt-oss-120b (USA, Released: 2025-08-05)

# 4. command-r (Canada, Released: 2024-03-11)

**Primary Diagnosis:** Acute Pyelonephritis (ICD-10: N10) - Confidence: 0.75 **Differential Diagnoses:** 

- Interstitial Cystitis (ICD: N30.9) 0.6
- Bladder Cancer (ICD: C67) 0.4
- Renal Abcess (ICD: N14.9) 0.3

#### **Key Clinical Findings:**

- Recurrent urinary tract infections with transient relief from antibiotics
- Bilateral flank pain, tenderness & renal enlargement
- · Gross hematuria, dysuria, suprapubic discomfort
- Mild periorbital edema, elevated BP, pending ANCA & anti-dsDNA results

# 5. deepseek-chat (China, Released: 2024-12-20)

- 6. gemini-2.5-pro (USA, Released: 2024-12-19)
- 7. deepseek-r1 (China, Released: 2025-01-20)
- 8. sonar-deep-rese (USA, Released: 2025-03-07)
- 9. jamba-large-1.7 (Israel, Released: 2025-07-01)

Primary Diagnosis: Lupus Nephritis (ICD-10: N02.2) - Confidence: 0.8

**Differential Diagnoses:** 

- IgA Nephropathy (ICD: N02.0) 0.6
- Membranous Nephropathy (ICD: N02.3) 0.4
- Chronic Pyelonephritis (ICD: N11.9) 0.3

#### **Key Clinical Findings:**

- Bilateral renal enlargement
- Dysmorphic RBCs in urinalysis
- Low C3 and C4
- Positive ANA
- 10. gemini-2.5-flas (USA, Released: 2024-12-19)
- 11. mistral-large-2 (France, Released: 2024-11-01)

**Primary Diagnosis:** IgA Nephropathy (Berger's Disease) (ICD-10: N08.0) - Confidence: 0.85 **Differential Diagnoses:** 

- Lupus Nephritis (ICD: M32.14) 0.7
- Post-infectious Glomerulonephritis (ICD: N05.9) 0.6
- Membranoproliferative Glomerulonephritis (ICD: N01.7) 0.55

- Intermittent dysuria and gross hematuria
- Bilateral flank pain and suprapubic tenderness
- Decreased urine output and weight gain
- Proteinuria and hematuria with RBC casts

### 12. command-r-plus (Canada, Released: 2024-04-04)

Primary Diagnosis: Glomerulonephritis (ICD-10: N03.9) - Confidence: 0.7

#### **Differential Diagnoses:**

- Interstitial Nephritis (ICD: N16.1) 0.6
- Nephrolithiasis (Kidney Stones) (ICD: N20.9) 0.5
- Urinary Tract Infection (UTI) (ICD: N39.0) 0.4

#### **Key Clinical Findings:**

- · Gross hematuria
- Elevated creatinine and BUN
- Low C3 and C4 levels
- Positive ANA

### 13. wizardlm-2-8x22 (USA, Released: 2024-04-15)

**Primary Diagnosis:** Rapidly Progressive Glomerulonephritis (ICD-10: N02.0) - Confidence: 0.7 **Differential Diagnoses:** 

- IgA Nephropathy (ICD: N03.2) 0.5
- Lupus Nephritis (ICD: N05.1) 0.6
- Post-infectious Glomerulonephritis (ICD: N05.9) 0.4

#### **Key Clinical Findings:**

- Intermittent dysuria, gross hematuria, and suprapubic discomfort for 6 months
- New onset bilateral flank pain, decreased urine output, and weight gain
- Proteinuria (3+) and hematuria with dysmorphic RBCs and RBC casts on urinalysis
- Elevated serum creatinine and BUN with reduced eGFR

## 14. grok-2-1212 (USA, Released: 2024-12-12)

Primary Diagnosis: Lupus Nephritis (ICD-10: M32.14) - Confidence: 0.8

#### **Differential Diagnoses:**

- IgA Nephropathy (ICD: N02.8) 0.6
- ANCA-Associated Vasculitis (ICD: M31.3) 0.5
- Chronic Interstitial Nephritis (ICD: N11.9) 0.4

- Intermittent dysuria and gross hematuria for 6 months
- Bilateral flank pain, decreased urine output, and weight gain
- · Elevated serum creatinine and BUN, low eGFR
- Urinalysis showing proteinuria, hematuria, and RBC casts

### 15. gemma-2-9b-it (USA, Released: 2024-06-27)

Primary Diagnosis: Systemic Lupus Nephritis (ICD-10: N17.0) - Confidence: 0.8

#### **Differential Diagnoses:**

- Acute Interstitial Nephritis (ICD: N17.9) 0.15
- Renal Cell Carcinoma (ICD: C64.9) 0.05
- Glomerulonephritis (Other) (ICD: N03.9) 0.1

#### **Key Clinical Findings:**

- Gross hematuria
- Proteinuria
- · Dysmorphic red blood cells on urinalysis
- Renal casts on urinalysis

### 16. gpt-4o (USA, Released: 2024-05-13)

Primary Diagnosis: IgA Nephropathy (ICD-10: N02.8) - Confidence: 0.8

#### **Differential Diagnoses:**

- Lupus Nephritis (ICD: M32.14) 0.7
- Alport Syndrome (ICD: Q87.81) 0.6
- Acute Glomerulonephritis (ICD: N00.9) 0.5

#### **Key Clinical Findings:**

- · Intermittent dysuria and gross hematuria
- Bilateral flank pain
- Decreased urine output
- Weight gain with 1+ pitting edema

## 17. gemini-2.5-flas (USA, Released: 2024-12-19)

**Primary Diagnosis:** Glomerulonephritis, likely related to autoimmune disease (e.g., Lupus Nephritis) (ICD-10: N08.5) - Confidence: 0.9

#### **Differential Diagnoses:**

- IgA Nephropathy (ICD: N02.8) 0.7
- Post-infectious Glomerulonephritis (ICD: N08.0) 0.5
- Alport Syndrome (ICD: Q87.81) 0.6

- 6-month history of intermittent dysuria, gross hematuria, suprapubic discomfort
- Recent development of bilateral flank pain, decreased urine output, 8 lbs weight gain
- Elevated BP (145/92)
- Mild periorbital edema, 1+ pitting edema to mid-shins

### 18. Ilama-3.2-3b-in (USA, Released: 2024-09-25)

**Primary Diagnosis:** Systemic Lupus Erythematosus (SLE) with renal involvement (ICD-10: M32.0) - Confidence: 0.9

#### **Differential Diagnoses:**

- Interstitial Nephritis (ICD: N17.0) 0.6
- Glomerulonephritis (ICD: N05.0) 0.5
- Chronic Pyelonephritis (ICD: N35.0) 0.4

#### **Key Clinical Findings:**

- Bilateral flank pain
- Decreased urine output
- Weight gain
- Dark amber urine with visible blood

### 19. gpt-4o-mini (USA, Released: 2024-07-18)

Primary Diagnosis: Glomerulonephritis (ICD-10: N00) - Confidence: 0.8

#### **Differential Diagnoses:**

- Interstitial Nephritis (ICD: N10) 0.7
- Renal Stones (ICD: N20) 0.5
- Urinary Tract Infection (ICD: N39.0) 0.4

#### **Key Clinical Findings:**

- Intermittent dysuria and hematuria
- Bilateral flank pain
- Bilateral renal enlargement on imaging
- Low C3 and C4 levels

## 20. qwen-2.5-coder- (China, Released: 2024-11-12)

**Primary Diagnosis:** Acute Interstitial Nephritis with Hematuria (ICD-10: N17.2) - Confidence: 0.85 **Differential Diagnoses:** 

- Renal Cell Carcinoma (RCC) (ICD: C64.9) 0.15
- IgA Nephropathy (ICD: N30.0) 0.1
- Systemic Lupus Erythematosus (SLE) (ICD: M32.9) 0.1

- Recurrent hematuria and dysuria for 6 months
- Bilateral flank pain, decreased urine output, and weight gain over 2 weeks
- Recent significant rise in creatinine and BUN

• Positive ANA with homogeneous pattern

### 21. claude-3-opus-2 (USA, Released: 2024-02-29)

**Primary Diagnosis:** Lupus nephritis (ICD-10: M32.14) - Confidence: 0.8 **Differential Diagnoses:** 

- Acute interstitial nephritis (ICD: N12) 0.6
- IgA nephropathy (ICD: N02.8) 0.5
- Granulomatosis with polyangiitis (ICD: M31.3) 0.4

#### **Key Clinical Findings:**

- Recurrent dysuria, hematuria, and suprapubic discomfort
- Bilateral flank pain and decreased urine output
- Proteinuria, dysmorphic RBCs, and RBC casts on urinalysis
- Elevated creatinine and decreased eGFR

## 22. lfm-40b (USA, Released: 2024-10-29)